Literature DB >> 26195723

Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.

Kosj Yamoah1, Michael H Johnson2, Voleak Choeurng2, Farzana A Faisal2, Kasra Yousefi2, Zaid Haddad2, Ashley E Ross2, Mohammed Alshalafa2, Robert Den2, Priti Lal2, Michael Feldman2, Adam P Dicker2, Eric A Klein2, Elai Davicioni2, Timothy R Rebbeck2, Edward M Schaeffer2.   

Abstract

PURPOSE: We studied the ethnicity-specific expression of prostate cancer (PC) -associated biomarkers to evaluate whether genetic/biologic factors affect ethnic disparities in PC pathogenesis and disease progression. PATIENTS AND METHODS: A total of 154 African American (AA) and 243 European American (EA) patients from four medical centers were matched according to the Cancer of the Prostate Risk Assessment postsurgical score within each institution. The distribution of mRNA expression levels of 20 validated biomarkers reported to be associated with PC initiation and progression was compared with ethnicity using false discovery rate, adjusted Wilcoxon-Mann-Whitney, and logistic regression models. A conditional logistic regression model was used to evaluate the interaction between ethnicity and biomarkers for predicting clinicopathologic outcomes.
RESULTS: Of the 20 biomarkers examined, six showed statistically significant differential expression in AA compared with EA men in one or more statistical models. These include ERG (P < .001), AMACR (P < .001), SPINK1 (P = .001), NKX3-1 (P = .03), GOLM1 (P = .03), and androgen receptor (P = .04). Dysregulation of AMACR (P = .036), ERG (P = .036), FOXP1 (P = .041), and GSTP1 (P = .049) as well as loss-of-function mutations for tumor suppressors NKX3-1 (P = .025) and RB1 (P = .037) predicted risk of pathologic T3 disease in an ethnicity-dependent manner. Dysregulation of GOLM1 (P = .037), SRD5A2 (P = .023), and MKi67 (P = .023) predicted clinical outcomes, including 3-year biochemical recurrence and metastasis at 5 years. A greater proportion of AA men than EA men had triple-negative (ERG-negative/ETS-negative/SPINK1-negative) disease (51% v 35%; P = .002).
CONCLUSION: We have identified a subset of PC biomarkers that predict the risk of clinicopathologic outcomes in an ethnicity-dependent manner. These biomarkers may explain in part the biologic contribution to ethnic disparity in PC outcomes between EA and AA men.
© 2015 by American Society of Clinical Oncology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26195723      PMCID: PMC4550692          DOI: 10.1200/JCO.2014.59.8912

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  46 in total

1.  Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.

Authors:  Annukka Paju; Kristina Hotakainen; Yue Cao; Timo Laurila; Virgil Gadaleanu; Akseli Hemminki; Ulf-Håkan Stenman; Anders Bjartell
Journal:  Eur Urol       Date:  2007-02-05       Impact factor: 20.096

2.  Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer.

Authors:  Sooryanarayana Varambally; Bharathi Laxman; Rohit Mehra; Qi Cao; Saravana M Dhanasekaran; Scott A Tomlins; Jill Granger; Adaikkalam Vellaichamy; Arun Sreekumar; Jianjun Yu; Wenjuan Gu; Ronglai Shen; Debashis Ghosh; Lorinda M Wright; Raleigh D Kladney; Rainer Kuefer; Mark A Rubin; Claus J Fimmel; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

3.  Delineation of TMPRSS2-ERG splice variants in prostate cancer.

Authors:  Ying Hu; Albert Dobi; Taduru Sreenath; Christopher Cook; Atekelt Y Tadase; Lakshmi Ravindranath; Jennifer Cullen; Bungo Furusato; Yongmei Chen; Rajesh L Thangapazham; Ahmed Mohamed; Chen Sun; Isabell A Sesterhenn; David G McLeod; Gyorgy Petrovics; Shiv Srivastava
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

4.  Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

Authors:  R Jeffrey Karnes; Eric J Bergstralh; Elai Davicioni; Mercedeh Ghadessi; Christine Buerki; Anirban P Mitra; Anamaria Crisan; Nicholas Erho; Ismael A Vergara; Lucia L Lam; Rachel Carlson; Darby J S Thompson; Zaid Haddad; Benedikt Zimmermann; Thomas Sierocinski; Timothy J Triche; Thomas Kollmeyer; Karla V Ballman; Peter C Black; George G Klee; Robert B Jenkins
Journal:  J Urol       Date:  2013-06-11       Impact factor: 7.450

5.  African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?

Authors:  Debasish Sundi; Ashley E Ross; Elizabeth B Humphreys; Misop Han; Alan W Partin; H Ballentine Carter; Edward M Schaeffer
Journal:  J Clin Oncol       Date:  2013-06-17       Impact factor: 44.544

6.  TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.

Authors:  Sven Perner; Juan-Miguel Mosquera; Francesca Demichelis; Matthias D Hofer; Pamela L Paris; Jeff Simko; Colin Collins; Tarek A Bismar; Arul M Chinnaiyan; Angelo M De Marzo; Mark A Rubin
Journal:  Am J Surg Pathol       Date:  2007-06       Impact factor: 6.394

7.  Multiple loci identified in a genome-wide association study of prostate cancer.

Authors:  Gilles Thomas; Kevin B Jacobs; Meredith Yeager; Peter Kraft; Sholom Wacholder; Nick Orr; Kai Yu; Nilanjan Chatterjee; Robert Welch; Amy Hutchinson; Andrew Crenshaw; Geraldine Cancel-Tassin; Brian J Staats; Zhaoming Wang; Jesus Gonzalez-Bosquet; Jun Fang; Xiang Deng; Sonja I Berndt; Eugenia E Calle; Heather Spencer Feigelson; Michael J Thun; Carmen Rodriguez; Demetrius Albanes; Jarmo Virtamo; Stephanie Weinstein; Fredrick R Schumacher; Edward Giovannucci; Walter C Willett; Olivier Cussenot; Antoine Valeri; Gerald L Andriole; E David Crawford; Margaret Tucker; Daniela S Gerhard; Joseph F Fraumeni; Robert Hoover; Richard B Hayes; David J Hunter; Stephen J Chanock
Journal:  Nat Genet       Date:  2008-02-10       Impact factor: 38.330

8.  Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.

Authors:  Nicholas Erho; Anamaria Crisan; Ismael A Vergara; Anirban P Mitra; Mercedeh Ghadessi; Christine Buerki; Eric J Bergstralh; Thomas Kollmeyer; Stephanie Fink; Zaid Haddad; Benedikt Zimmermann; Thomas Sierocinski; Karla V Ballman; Timothy J Triche; Peter C Black; R Jeffrey Karnes; George Klee; Elai Davicioni; Robert B Jenkins
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

9.  Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.

Authors:  J Cuzick; D M Berney; G Fisher; D Mesher; H Møller; J E Reid; M Perry; J Park; A Younus; A Gutin; C S Foster; P Scardino; J S Lanchbury; S Stone
Journal:  Br J Cancer       Date:  2012-02-23       Impact factor: 7.640

10.  Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study.

Authors:  D M Berney; A Gopalan; S Kudahetti; G Fisher; L Ambroisine; C S Foster; V Reuter; J Eastham; H Moller; M W Kattan; W Gerald; C Cooper; P Scardino; J Cuzick
Journal:  Br J Cancer       Date:  2009-03-24       Impact factor: 7.640

View more
  60 in total

1.  Radiation therapy to the primary tumor in locally advanced prostate cancer is not "closing the barn door after the horse has bolted".

Authors:  Nicholas G Zaorsky; Mark A Hallman; Marc C Smaldone
Journal:  Ann Transl Med       Date:  2015-10

2.  Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences.

Authors:  Walter Rayford; Alp Tuna Beksac; Jordan Alger; Mohammed Alshalalfa; Mohsen Ahmed; Irtaza Khan; Ugo G Falagario; Yang Liu; Elai Davicioni; Daniel E Spratt; Edward M Schaeffer; Felix Y Feng; Brandon Mahal; Paul L Nguyen; Robert B Den; Mark D Greenberger; Randy Bradley; Justin M Watson; Matthew Beamer; Lambros Stamatakis; Darrell J Carmen; Shivanshu Awasthi; Jonathan Hwang; Rachel Weil; Harri Merisaari; Nihal Mohamed; Leslie A Deane; Dimple Chakravarty; Kamlesh K Yadav; Kosj Yamoah; Sujit S Nair; Ashutosh K Tewari
Journal:  Commun Biol       Date:  2021-06-03

3.  RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression.

Authors:  Yongquan Wang; Jianghua Wang; Li Zhang; Omer Faruk Karatas; Longjiang Shao; Yiqun Zhang; Patricia Castro; Chad J Creighton; Michael Ittmann
Journal:  Cancer Res       Date:  2017-06-13       Impact factor: 12.701

Review 4.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

5.  Contemporary Role of the Decipher® Test in Prostate Cancer Management: Current Practice and Future Perspectives.

Authors:  Deepansh Dalela; Björn Löppenberg; Akshay Sood; Jesse Sammon; Firas Abdollah
Journal:  Rev Urol       Date:  2016

6.  A CD24-p53 axis contributes to African American prostate cancer disparities.

Authors:  Wei Liu; Yue Zhang; Shi Wei; Sejong Bae; Wei-Hsiung Yang; Gary J Smith; James L Mohler; Elizabeth T H Fontham; Jeannette T Bensen; Guru P Sonpavde; Guo-Yun Chen; Runhua Liu; Lizhong Wang
Journal:  Prostate       Date:  2020-03-13       Impact factor: 4.104

7.  Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.

Authors:  Varadha Balaji Venkadakrishnan; Adam D DePriest; Sangeeta Kumari; Dhirodatta Senapati; Salma Ben-Salem; Yixue Su; Giridhar Mudduluru; Qiang Hu; Eduardo Cortes; Elena Pop; James L Mohler; Gissou Azabdaftari; Kristopher Attwood; Rajal B Shah; Christina Jamieson; Scott M Dehm; Cristina Magi-Galluzzi; Eric Klein; Nima Sharifi; Song Liu; Hannelore V Heemers
Journal:  Oncogene       Date:  2019-02-11       Impact factor: 9.867

8.  Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations.

Authors:  Franklin W Huang; Juan Miguel Mosquera; Andrea Garofalo; Coyin Oh; Maria Baco; Ali Amin-Mansour; Bokang Rabasha; Samira Bahl; Stephanie A Mullane; Brian D Robinson; Saud Aldubayan; Francesca Khani; Beerinder Karir; Eejung Kim; Jeremy Chimene-Weiss; Matan Hofree; Alessandro Romanel; Joseph R Osborne; Jong Wook Kim; Gissou Azabdaftari; Anna Woloszynska-Read; Karen Sfanos; Angelo M De Marzo; Francesca Demichelis; Stacey Gabriel; Eliezer M Van Allen; Jill Mesirov; Pablo Tamayo; Mark A Rubin; Isaac J Powell; Levi A Garraway
Journal:  Cancer Discov       Date:  2017-05-17       Impact factor: 39.397

9.  MNX1 Is Oncogenically Upregulated in African-American Prostate Cancer.

Authors:  Li Zhang; Jianghua Wang; Yongquan Wang; Yiqun Zhang; Patricia Castro; Longjiang Shao; Arun Sreekumar; Nagireddy Putluri; Nilanjan Guha; Saligrama Deepak; Arunkumar Padmanaban; Chad J Creighton; Michael Ittmann
Journal:  Cancer Res       Date:  2016-08-30       Impact factor: 12.701

10.  Prognostic Utility of a New mRNA Expression Signature of Gleason Score.

Authors:  Jennifer A Sinnott; Sam F Peisch; Svitlana Tyekucheva; Travis Gerke; Rosina Lis; Jennifer R Rider; Michelangelo Fiorentino; Meir J Stampfer; Lorelei A Mucci; Massimo Loda; Kathryn L Penney
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.